Paris, France, January 31, 2013 - OSE Pharma SA, dedicated to severe orphan lung diseases announces the allowance of its first patent in Europe related to OSE2101, its targeted cancer
immune therapy product in phase 3 for lung cancer - the product OSE2101 developed by OSE Pharma targets 5 tumor antigens with 10 epitopes -an epitope is a small peptide or a fragment of tumor antigen. The patent covers a composition comprising these epitopes. They produce a response of particular cells named T cytotoxic, able to destroy the tumor cells expressing these tumor antigens.The 5 tumor associated antigens (HER2/neu; P53; CEA; MAGE2; MAGE3) were selected due to the poor prognosis established when overexpressed in particular in lung cancer named Non-Small Cell Lung Cancer (NSCLC) and for the increasing risk when these Tumor antigens are associated.
The lung cancer is the leading cause of cancer death in the world and the Non Small Cell Lung cancers(NSCLC 88% of lung cancer) amounted to 1,41 million new cases each year with a high level of mortality: 1.21 million deaths. The HLA A2 positive patients (HLA A2 is a requirement for the immune T cytotoxic response) are the target population of OSE2101 and are representing 45% of the NSCLC population. This HLA A2 biomarker is a poor prognosis factor associated with an increasing invasive risk. This population of HLA A2 positive patients is the basis of the demand of an orphan drug status filed by OSE Pharma. The need of innovative drug is critically needed due to this aggressive NSCLC disease often discovered at late stage. Despite aggressive treatments, the 5-year relative survival rates are about 24% for patients with regional disease and less than 4% for patients with metastatic disease... OSE Pharma's Press Release -
